Mizuho Cuts Medline (MDLN) Price Target to $45

On October 22, 2026, Mizuho reaffirmed its Outperform rating on Medline Inc. NASDAQ: MDLN, while lowering its price target from $48.0 to $45.0. Research notes from the firm detail its ongoing stance on the medical supply company as shares trade near $34.65.

MDLN Medline Inc.

$35.31 ▼ -13.07% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Mizuho's Call on Medline Inc.

Mizuho issued a note on October 22, 2026, maintaining an Outperform rating on Medline while adjusting its target down to $45.0 from the previous level of $48.0. The forward-looking rating represents the firm's current view on the stock's potential performance.

Other Institutional Activity in Medline Inc.

Large funds continue to adjust their holdings in Medline. Banque Pictet & Cie grew its holdings by 142,939 shares, ending with 7,455,089 shares worth about $258.7 million. Carlyle Group Inc. held steady with 187,083,713 shares valued at about $6.5 billion. Blackstone Inc reduced its stake by 22,404,953 shares to finish with 101,791,008 shares worth roughly $3.5 billion. H&f Corporate Investors X, Ltd. cut its position by 15,599,963 shares, leaving it with 70,874,326 shares valued at about $2.5 billion. Lone Pine Capital Llc lifted its investment by 9,179,113 shares to hold 20,968,367 shares worth roughly $725.0 million.

Medline Inc. Stock Down 1.9%

Medline recently changed hands at $34.65, staying close to its closing price of $34.58 on October 22, 2026. The stock sits below its 50-day moving average of $34.72 and beneath its 200-day moving average of $39.94. The company carries a market capitalization of $30.33 billion.

Recent Earnings

Medline reported trailing twelve month revenue of $29.94 billion alongside earnings of $0.40 per share. The company posted a net profit margin of 2.3% and a return on equity of 4.9%. Management scheduled the next earnings report for November 4, 2026.

Dividend

The company maintains a dividend payout ratio of 0.0% with a dividend yield of 0.0%.

Insider Buying and Selling at Medline Inc.

Gic Private Ltd, a beneficial owner of more than 10% of a class of security, executed several transactions in the months leading up to the analyst update. The holder parted with 590,284 shares at $35.58 on August 7, 2026, valued at $21.0 million. Next, the entity shed 1.6 million shares at $35.80 on August 14, 2026, totaling $57.3 million. A further disposition involved 20,678,630 shares on October 6, 2026, worth about $721.6 million. Finally, the holder sold 7,816,987 shares at $35.15 on October 8, 2026, for a value of $274.8 million.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on Medline in recent months. JP Morgan maintained an Overweight rating while lowering its target from $53.0 to $46.0 on August 12, 2026. BTIG reiterated a Buy rating with a $55.0 target on August 27, 2026. UBS kept a Buy rating while trimming its target from $45.0 to $43.0 on September 25, 2026. Barclays maintained an Overweight rating and moved its target from $45.0 to $43.0 on October 9, 2026. Overall, the stock carries a consensus recommendation key of buy, with 26 analyst opinions and a mean price target of $44.31.

About Medline Inc.

Medline Inc. manufactures medical-surgical products for hospitals, surgery centers, physician offices, and nursing homes across the United States and international markets. The firm operates through its Medline Brand and Supply Chain Solutions segments, producing surgical solutions, frontline care items, and laboratory diagnostics.

Bottom Line

Investors are looking ahead to Medline's upcoming earnings release on November 4, 2026, for further updates on financial performance. Market participants will also monitor subsequent institutional filings and analyst revisions as the stock trades near its recent levels.